Anika Therapeutics logo
Anika Therapeutics ANIK
$ 14.75 0.0%

Quarterly report 2025-Q3
added 11-05-2025

report update icon

Anika Therapeutics Net Debt 2011-2026 | ANIK

Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]

Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.

Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.

Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.

Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.

Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.

Annual Net Debt Anika Therapeutics

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-46 M -57.5 M -75.1 M - -135 M -89 M -133 M -104 M -111 M -100 M -63.3 M -34.5 M -24.6 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-24.6 M -135 M -81.1 M

References

  1. Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.

Net Debt of other stocks in the Biotechnology industry

Issuer Net Debt Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
163 M - 2.43 % $ 254 M germanyGermany
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
-34.7 M $ 3.6 1.34 % $ 8.66 B australiaAustralia
Aytu BioScience Aytu BioScience
AYTU
-19.9 M $ 2.66 - $ 16.7 M usaUSA
BioNTech SE BioNTech SE
BNTX
-973 M $ 91.28 - $ 27.2 B germanyGermany
I-Mab I-Mab
IMAB
-1.06 B - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
-402 M - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
2.27 M - 2.54 % $ 160 B franceFrance
Burford Capital Limited Burford Capital Limited
BUR
-135 M $ 4.48 - $ 736 M britainBritain
Biophytis SA Biophytis SA
BPTS
-4.01 M - -13.47 % $ 169 M franceFrance
Cerus Corporation Cerus Corporation
CERS
-6.9 M $ 1.85 - $ 353 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-6.17 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-824 K - -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
114 M - -24.86 % $ 820 K usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
-85.6 M $ 1.67 - $ 196 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
-26.5 M $ 31.37 - $ 2.08 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
-5.64 M $ 0.44 - $ 5.04 M israelIsrael
Advaxis Advaxis
ADXS
3.42 M - -9.65 % $ 45.9 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
31.1 M - - $ 86.2 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
-13.6 M $ 2.32 - $ 1.03 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
246 M - - - russiaRussia
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
-706 M $ 24.98 - $ 3.05 B usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
263 K $ 10.14 - $ 135 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
-16.6 M $ 1.58 - $ 106 M usaUSA
Curis Curis
CRIS
-3.44 M $ 0.53 - $ 6.98 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
-53 M $ 37.7 - $ 3.55 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
-141 M $ 49.15 - $ 4.42 B schweizSchweiz
Aeterna Zentaris Aeterna Zentaris
AEZS
-65.1 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
12.6 M - -10.17 % $ 12.2 K usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
-28.7 M $ 4.4 - $ 607 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
-2.99 M $ 0.86 - $ 5.79 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-30.2 M - - $ 1.01 B usaUSA
Cue Biopharma Cue Biopharma
CUE
-22.9 M $ 0.18 - $ 17.1 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-36 M - - $ 26.5 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
-188 M $ 20.36 - $ 2.84 B franceFrance
AIkido Pharma AIkido Pharma
AIKI
-31.2 M - 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
-5.53 M - -45.71 % $ 1.2 M canadaCanada
Denali Therapeutics Denali Therapeutics
DNLI
-158 M $ 19.38 - $ 3.19 B usaUSA
Dyadic International Dyadic International
DYAI
-6.38 M $ 0.87 -2.8 % $ 31.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-340 M - - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-783 M - - $ 867 M germanyGermany
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
-5.45 M $ 3.54 - $ 238 B britainBritain
Akouos Akouos
AKUS
-92.9 M - 0.23 % $ 488 M usaUSA
Entera Bio Ltd. Entera Bio Ltd.
ENTX
-7.85 M $ 1.19 - $ 55.5 M israelIsrael
Equillium Equillium
EQ
-29.6 M $ 2.01 - $ 115 M usaUSA
Allakos Allakos
ALLK
-25 M - - $ 28.6 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-29.5 M - 3.16 % $ 1.9 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
-604 M $ 330.34 - $ 43.3 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-63.9 M - - $ 2.17 B usaUSA
Fate Therapeutics Fate Therapeutics
FATE
31.2 M $ 1.19 - $ 141 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-3.44 M - 10.36 % $ 9.8 M usaUSA